Zydus Lifesciences has announced positive topline results from its completed EVIDENCES-X™ Phase II(b) clinical trial
Zydus Lifesciences Limited has launched REVAHALE™ (revefenacin), a once-daily nebulised long-acting muscarinic antagonist (LAMA) for
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration
Zydus Lifesciences Limited has received Orphan Drug Designation (ODD) from the United States Food and
Zydus Lifesciences Ltd, through its wholly-owned subsidiary, has entered into a strategic agreement to acquire
